发明名称 2-substituted-<i>p</i>-quinone derivatives for treatment of oxidative stress diseases
摘要 Methods of treating or suppressing oxidative stress diseases including mitochondrial diseases, impaired energy processing disorders, neurodegenerative diseases and diseases of aging are disclosed, as well as compounds useful in the methods of the invention, such as 2-substituted-p-quinone derivatives as disclosed herein.
申请公布号 US9090576(B2) 申请公布日期 2015.07.28
申请号 US201414223842 申请日期 2014.03.24
申请人 Edison Pharmaceuticals, Inc. 发明人 Hinman Andrew W.;Wesson Kieron E.;Jankowski Orion D.;Shrader William D.;Lee Edgar P.
分类号 C07C275/22;C07D295/195;C07C45/00;C07C45/30;C07C205/34;C07C233/31;C07C233/61;C07C233/76;C07C235/34;C07C235/40;C07C235/78;C07C255/57;C07C255/60;C07C311/03;C07C311/16;C07C311/29;C07D209/08;C07D211/46;C07D213/56;C07D213/75;C07D213/82;C07D215/08;C07D217/06;C07D295/215;C07D311/74;C07D317/66;C07D319/18;C07D339/04;C07C275/30;C07C311/17 主分类号 C07C275/22
代理机构 Squire Patton Boggs (US) LLP 代理人 Squire Patton Boggs (US) LLP
主权项 1. A compound of Formula I:where, R is selected from the group consisting of: where the * indicates the point of attachment of R to the remainder of the molecule; M and M′ are independently selected from the group consisting of hydrogen, —C(O)—R′, —C(O)—(C2-C6)-alkenyl, —C(O)—(C2-C6)-alkynyl, —C(0)-aryl, —C(O)—heterocyclyl, —C(O)O—R′, —C(O)NR′R″, —SO2OR′, —SO2(C1-C6)-alkyl, —SO2(C1-C6)-haloalkyl, —SO2-aryl, —SO2NR′R″, —P(O)(OR′)(OR″), and C-linked mono-or di-peptide, where R′ and R″ are independently of each other hydrogen or (C1-C6)-alkyl optionally substituted with one or more substituents independently selected from the group consisting of —OH, —NH2, —NH(C1-C4)-alkyl, —N((C1-C4)-alkyl)2, —C(O)OH, —C(O)O—(C1-C4)-alkyl, and halogen; R1 is (C1-C6)-alkyl, (C1-C6)-alkoxy, heterocyclyl, or aryl, where the heterocyclyl and the aryl are optionally substituted with one or more substituents independently selected from the group consisting of —OH, (C1-C6)-alkyl, (C1-C6)-alkoxy, hydroxyl-(C1-C6)alkyl-, alkoxy(C1-C6)-alkyl-, —NR10R10′, —(C1-C6)-alkyl —NR10R10′, —C(O)—(C1-C6)-alkyl, —C(O)—OH, —C(O)O—(C1-C6)-alkyl,—C(O)NR10R10′, —NR11C(O)R10, —NR11C(O)NR10R10—NR11(C(O)OR10, —SO2(C1-C6)-alkyl, —SO2 (C1-C6)-haloalkyl, —SO2-aryl, —SO2NR10R10′, CN, haloalkyl, and halogen; R2 is hydrogen, (C1-C6)-alkyl, or (C1-C6)-alkoxy; R3 is unsubstituted (C1-C6)-alkyl; R4 is hydrogen or (C1-C6)-alkyl; R5 is —C(O)NR6R7; R6 is hydrogen, (C1-C6)-alkyl, aryl, or heterocyclyl, where (C1-C6)-alkyl is optionally substituted with one or more substituents independently selected from the group consisting of: —OR11, —SR11, —CN, —F, —Cl, —Br, —I, —NR10R10′, (C3-C6)-cycloalkyl, aryl, heterocyclyl, —C(O)—R11, —C(O)—(C0-C6)-alkyl-aryl, —C(O)O—R11, —C(O)—O—(C0-C6)-alkyl-aryl, —C(O)N—R10R10′, C(O)NR11-(C0-C6)-alkyl-aryl, —NR11C(O)—R10, and —NR11C(O)—(C0-C6)-alkyl-aryl; wherein the aryl and heterocyclyl ring substituents may be further substituted with one or more groups independently selected from the group consisting of (C1-C6)-alkyl, halogen, (C1-C6) -haloalkyl, CN, oxo, hydroxy, (C1-C6)-alkoxy, —C(O)—(C1-C6) -alkyl, and —C(O)—O—(C1-C6)-alkyl; and where aryl and heterocyclyl are optionally substituted with (C1-C6)-alkyl, halogen, (C1-C6)-haloalkyl, CN, oxo, hydroxy, (C1-C6)-alkoxy, —C(O)—(C1-C6)-alkyl or —C(O)—O—(C1-C6)-alkyl; R7 is hydrogen or (C1-C6)-alkyl; or R6 and R7 together with the atom to which they are attached form a saturated or unsaturated 3-8 membered ring, optionally incorporating one, two, or three additional heteroatoms independently selected from the group consisting of N, O, and S atoms, and optionally substituted with oxo, —OH, —SH, —F, —Cl, —Br, —I, —NR11R11′, (C1-C6)-alkyl, (C1-C6)-alkoxy, (C1-C6)-thioalkyl, (C1-C6)-haloalkyl, hydroxy-(C1-C6)-alkyl, —C(O)—H, —C(O)—(C1-C6)-alkyl, —C(O)OH, or —C(O)O—(C1-C6)-alkyl; R10 and R10′ are independently selected from the group consisting of H, (C1-C6)-alkyl, (C1-C6) -haloalkyl, aryl, -aryl-(C1-C6)-alkyl, heteroaryl, heterocyclyl, —C(O)—H, —C(O)—(C1-C6)-alkyl, —C(O)-aryl, and —C(O)—(C1-C6)-alkyl-aryl; or R10 and R10′ together with the atom to which they are attached form a saturated or unsaturated 3-8 membered ring, optionally incorporating one, two, or three additional heteroatoms independently selected from the group consisting of N, O, and S atoms, and optionally substituted with one or more substituents independently selected from the group consisting of oxo, —OH, —F,—Cl, —Br, —I, —NR11R11′, (C1 C6)-alkyl, (C1-C6)-alkoxy, (C1-C6)-haloalkyl, hydroxy -(C1-C6)-alkyl-, —C(O)—H, —C(O )—(C1-C6)-alkyl, —C(O)OH, and —C(O)O—(C1-C6)-alkyl; R11 and R11′ are independently selected from the group consisting of hydrogen and (C1-C6)-alkyl; and A is (C1-C4)-alkylene, (C2-C4)-alkenylene, or (C2-C4)-alkynylene;or a salt, a stereoisomer, or a mixture of stereoisomers thereof.
地址 Mountain View CA US